Vivos Therapeutics Inc (VVOS)

$5.74 -0.21 (-3.53%)
Market Cap 28.77M
Revenue (ttm) 13.80M
Net Income (ttm) -13.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -98.41%
Debt to Equity Ratio 0.00
Volume 625,600
Avg Vol 262,290
Day's Range N/A - N/A
Shares Out 4.84M
Stochastic %K 76%
Beta 7.51
Analysts Sell
Price Target $6.30

Latest News on VVOS

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 8:00 AM EST - 25 days ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 11:31 PM EST - 2 months ago

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Nov 13, 2024, 5:00 PM EST - 2 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Oct 8, 2024, 7:30 AM EDT - 3 months ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Sep 18, 2024, 7:00 AM EDT - 4 months ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 2:05 PM EDT - 5 months ago

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 14, 2024, 4:05 PM EDT - 5 months ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Aug 14, 2024, 7:30 AM EDT - 5 months ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Jun 27, 2024, 7:30 AM EDT - 7 months ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Jun 12, 2024, 7:30 AM EDT - 7 months ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

May 17, 2024, 9:02 PM EDT - 8 months ago

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

May 14, 2024, 4:05 PM EDT - 8 months ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

May 14, 2024, 7:30 AM EDT - 8 months ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Apr 9, 2024, 7:30 AM EDT - 10 months ago

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 11:10 PM EDT - 10 months ago

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Mar 28, 2024, 4:05 PM EDT - 10 months ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Mar 28, 2024, 7:30 AM EDT - 10 months ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Feb 6, 2024, 7:30 AM EST - 1 year ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Jan 8, 2024, 7:30 AM EST - 1 year ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Dec 11, 2023, 7:30 AM EST - 1 year ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Nov 29, 2023, 11:09 AM EST - 1 year ago

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Nov 29, 2023, 7:44 AM EST - 1 year ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Nov 29, 2023, 7:30 AM EST - 1 year ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript

Nov 17, 2023, 7:12 PM EST - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 14, 2023, 4:05 PM EST - 1 year ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Nov 9, 2023, 4:30 PM EST - 1 year ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Vivos Therapeutics Closes $4 Million Private Placement

Nov 2, 2023, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Closes $4 Million Private Placement

Vivos Therapeutics Announces Reverse Stock Split

Oct 26, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Announces Reverse Stock Split

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Oct 24, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Oct 11, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Oct 5, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

Oct 4, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference

Oct 2, 2023, 7:30 AM EDT - 1 year ago

New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference

Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update

Aug 16, 2023, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call

Aug 16, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call

Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call

Aug 14, 2023, 5:06 PM EDT - 1 year ago

Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call

Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call

Aug 10, 2023, 8:31 PM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call

Vivos Therapeutics, Inc. (VVOS) Q1 2023 Earnings Call Transcript

Jun 9, 2023, 12:24 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q1 2023 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update

Jun 8, 2023, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call

Jun 6, 2023, 4:30 PM EDT - 1 year ago

Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call

Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos' POD® Appliance Treatment

May 1, 2023, 7:30 AM EDT - 1 year ago

Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos' POD® Appliance Treatment

Vivos Therapeutics, Inc. (VVOS) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 6:05 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q4 2022 Earnings Call Transcript

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

Mar 30, 2023, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call

Mar 30, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call

Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference

Mar 8, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference

Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC

Mar 1, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC

Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

Feb 21, 2023, 4:05 PM EST - 2 years ago

Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 20, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements

Vivos Therapeutics Closes $8 Million Private Placement

Jan 9, 2023, 4:45 PM EST - 2 years ago

Vivos Therapeutics Closes $8 Million Private Placement

Vivos Therapeutics Announces Pricing of $8 Million Private Placement

Jan 5, 2023, 8:10 AM EST - 2 years ago

Vivos Therapeutics Announces Pricing of $8 Million Private Placement